Skip to main content
TTKHLTCARE · Health Care · 2026-08-07

TTK Healthcare Ltd

Stage 1 · wk 10In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹1,084.8
-0.85% today
₹1,533 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective Devices segment manufactures and markets sexual wellness products, including male contraceptives under the Skore brand name, and other allied products. The Foods segment engages in the manufacturing and marketing of food products, including papads under the Fryums name; and cereal, potato, rice, pulses, and corn-based products. The Others segment prints and publishes maps, atlases, guidebooks, and educational publications under the TTK brand name. The company was founded in 1928 and is headquartered in Chennai, India. TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd.

Visit company website →
P/E (TTM)
21.0
Forward —
Earnings Growth (YoY)
-37.1%
Revenue +2.2%
Dividend Yield
1.14%
P/B 1.2
vs 52W High
-13.8%
₹739.6 lo₹1,258.2 hi
13.8% below 52W high — pullback range
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 10
1w13w26w
Week 10 — base building
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
11.5%
200 DMA: ₹973.1 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.19x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 trending up · +6.8% vs MA50 +5.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 30w
S4 23w
S4 41w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 9w → S3 1w → S2 3w → S3 12w → S2 30w → S3 10w → S2 13w → S3 6w → S4 23w → S1 12w → S4 41w → S1 10w current
Total tracked: 169 weeks across 12 stage runs.
1M
+18.0%
3M
+17.0%
6M
+12.7%
YTD
+4.9%
1Y
-13.6%
Scan Membership
Breakout Watch
Latest: 2024-08-08
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S1
Wk 10 · Vol x
2026-08-06S1
Wk 10 · Vol x
2026-08-05S1
Wk 10 · Vol x
2026-08-04S1
Wk 9 · Vol x
2026-08-03S1
Wk 9 · Vol x
2026-07-31S1
Wk 9 · Vol x
2026-07-30S1
Wk 9 · Vol x
2026-07-29S1
Wk 9 · Vol x
2026-07-28S1
Wk 8 · Vol x
2026-07-27S1
Wk 8 · Vol x
2026-07-24S1
Wk 8 · Vol x
2026-07-23S1
Wk 8 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹957.8
200 DMA
₹973.1
52W High
₹1,258.2
52W Low
₹739.6
5D Low
₹1,037.7
Resistance levels (recent highs)
20d High
₹1,094.1
60d High
₹1,094.1
120d High
₹1,094.1
250d High
₹1,217.1
Next resistance
+0.9%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.